Summary
No overall score for this company yet.
What speaks for it
- The price moves less than the market (beta 0.20).
What to watch
- It passes only 3 of the 9 points of the Piotroski financial health test.
- For every 100 USD of bills due within a year it has 33 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Is it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $21.6M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 0
- Hold 1
- Sell 0
No analyst has published a price target.
0.0% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.